Peripheral Artery Disease

Detailed Overview

PAD is a powerful clinical marker of systemic atherosclerotic burden, carrying a high risk of concomitant coronary artery and cerebrovascular disease. As the arterial lumen narrows due to atheroma formation, downstream tissues experience ischemia, initially during exertion (claudication) and eventually at rest. The progression to Critical Limb Ischemia (CLI) poses a significant risk for tissue loss and amputation. Management focuses on cardiovascular risk reduction, symptom improvement, and limb salvage.

Epidemiology & Demographics

Affects approximately 8-12 million people in the United States. Prevalence strongly increases with age, reaching >20% in individuals over 80. More common in non-Hispanic Black populations.

Etiological Mechanism

Atherosclerosis is the primary cause, driven by endothelial dysfunction, lipid accumulation, and chronic inflammation. Less common causes include fibromuscular dysplasia, vasculitis, and thromboembolism.

Primary Causes

Atherosclerotic plaque accumulation in the abdominal aorta, iliac, femoral, popliteal, and tibial arteries.

• Smoking: The strongest risk factor; increases risk by 2-4 fold and accelerates progression to critical limb ischemia.
• Diabetes Mellitus: Increases PAD risk and specifically involves infrapopliteal (distal) vessels, compounding amputation risk.
• Dyslipidemia: High LDL and low HDL levels promote atheroma formation.
• Hypertension: Causes endothelial shear stress, facilitating lipid deposition in arterial walls.

The pathophysiologic hallmark is atherosclerosis. Endothelial injury allows LDL to enter the tunica intima, where macrophages engulf oxidized LDL to form foam cells, creating a fatty streak. Over time, smooth muscle proliferation and extracellular matrix deposition form a fibrous plaque that progressively narrows the arterial lumen. When stenosis exceeds 50-75%, distal perfusion pressures drop significantly during exercise, causing a mismatch in oxygen delivery. In advanced disease, resting blood flow becomes inadequate, leading to ischemic rest pain and tissue necrosis.

Characteristic Clinical Presentation

• Intermittent Claudication: Aching, cramping, or fatigue in the calves, thighs, or buttocks occurring with a consistent distance of walking and relieved strictly by 10 minutes of rest.
• Ischemic Rest Pain: Severe pain in the toes or forefoot occurring at rest, often waking the patient at night; relieved by dangling the leg over the side of the bed (gravity dependency).
• Erectile Dysfunction: Common in aortoiliac disease (Leriche syndrome).

Physical Examination Signs

• Diminished or absent femoral, popliteal, or pedal pulses.
• Arterial bruits over the iliac or femoral arteries.
• Skin changes: hair loss, shiny and atrophic skin, thickened toenails.
• Buerger's test: pallor on elevation of the limb and dependent rubor (reactive hyperemia) when the limb is lowered.

• Critical Limb Ischemia (CLI): Rest pain, ischemic ulcers, or gangrene requiring urgent revascularization.
• Amputation: Loss of limb or digits due to unsalvageable tissue necrosis.
• Myocardial Infarction / Stroke: Due to concurrent systemic atherosclerotic disease.

Diagnostic Criteria & Guidelines

Diagnosis is confirmed by an Ankle-Brachial Index (ABI) ≤ 0.90 at rest. An ABI of 0.91-0.99 is borderline. ABI >1.40 indicates noncompressible calcified vessels (common in diabetes) requiring Toe-Brachial Index (TBI).

Differential Diagnosis

• Lumbar Spinal Stenosis (Pseudoclaudication)
• Deep Vein Thrombosis (DVT)
• Diabetic Peripheral Neuropathy
• Venous Insufficiency

Laboratory Tests & Biomarkers

• Lipid Panel: Elevated LDL (e.g., >100 mg/dL), useful for guiding statin therapy rather than diagnosing PAD.
• Hemoglobin A1c: Elevated (e.g., >6.5%) indicating poorly controlled diabetes, a major risk factor.
• Homocysteine: May be elevated in younger patients with aggressive atherosclerosis.

Imaging Modalities & Findings

• Arterial Duplex Ultrasound: Focal velocity increases indicating >50% stenosis, typically biphasic or monophasic waveforms distal to the lesion.
• CT Angiography (CTA) / MR Angiography (MRA): Detailed anatomic mapping showing areas of calcification, occlusion, and collateral formation; used for surgical planning.
• Digital Subtraction Angiography (DSA): The gold standard invasive test; shows exact luminal narrowing, used therapeutically.

• Fontaine I
  Asymptomatic; disease detected only by abnormal ABI.
• Fontaine II (a/b)
  Intermittent claudication (IIa: pain on walking >200m; IIb: pain on walking <200m).
• Fontaine III
  Ischemic rest pain.
• Fontaine IV
  Ulceration or gangrene (Critical Limb Ischemia).

Second-Line & Adjunctive Therapy

Rivaroxaban 2.5 mg BID plus Aspirin 81 mg daily (COMPASS trial regimen) for high-risk patients to reduce cardiovascular events and major adverse limb events.

Surgical & Procedural Management

Endovascular revascularization (percutaneous transluminal angioplasty with or without stenting) for short segment lesions. Surgical bypass (e.g., femoro-popliteal bypass using autologous saphenous vein) for long, complex lesions or CLI.

Recommended Lifestyle Changes

• Immediate and complete smoking cessation; offer varenicline or bupropion.
• Structured walking program: walk until moderate pain, rest until pain subsides, then walk again.
• Meticulous foot care to prevent unhealed sores.
• Heart-healthy diet (Mediterranean or DASH) to control BP and lipids.

Patient Counseling & Advice

Emphasize that while leg pain is the primary symptom, the highest risk to their life is actually heart attack or stroke. Supervised exercise initially causes pain but is proven to significantly increase maximum walking distance over months.

Follow-Up & Monitoring Schedule

Clinical evaluation and resting ABI every 6-12 months. Monitor lipid profile and HbA1c to ensure targets are met (LDL < 70 mg/dL, HbA1c < 7%).

Preventive Strategies

Aggressive management of hypertension, diabetes, and hyperlipidemia in primary care. Routine ABI screening is recommended in patients >65 years, or >50 years with a history of smoking or diabetes.

Patients with claudication have a 5-year limb loss rate of only 1-2%, but a 5-year cardiovascular mortality rate of 15-30%. If disease progresses to CLI, 1-year amputation or mortality rate approaches 25-30% without intervention.